Publications

Search ACTG publications from 1/1/2006 to current.

Search

Filter results by

Found 688 results
Found 688 results.

2015

Thio CL, Smeaton L, Hollabaugh K, et al. "Comparison of HBV-active HAART regimens in an HIV-HBV multinational cohort: outcomes through 144 weeks." AIDS. 2015;29(10):1173-82.
Ofotokun I, Na LH, Landovitz RJ, et al. "Comparison of the metabolic effects of ritonavir-boosted darunavir or atazanavir versus raltegravir, and the impact of ritonavir plasma exposure: ACTG 5257." Clin. Infect. Dis.. 2015;60(12):1842-51.
Lalama CM, Jennings C, Johnson VA, et al. "Comparison of Three Different FDA-Approved Plasma HIV-1 RNA Assay Platforms Confirms the Virologic Failure Endpoint of 200 Copies per Milliliter Despite Improved Assay Sensitivity." J. Clin. Microbiol.. 2015;53(8):2659-66.
Shivakoti R, Yang W-T, Gupte N, et al. "Concurrent Anemia and Elevated C-Reactive Protein Predicts HIV Clinical Treatment Failure, Including Tuberculosis, After Antiretroviral Therapy Initiation." Clin. Infect. Dis.. 2015;61(1):102-10.
Schackman BR, Haas DW, Park SS, X Li C, Freedberg KA. "Cost-effectiveness of CYP2B6 genotyping to optimize efavirenz dosing in HIV clinical practice." Pharmacogenomics. 2015;16(18):2007-18.
Tenforde MW, Gupte N, Dowdy DW, et al. "C-reactive protein (CRP), interferon gamma-inducible protein 10 (IP-10), and lipopolysaccharide (LPS) are associated with risk of tuberculosis after initiation of antiretroviral therapy in resource-limited settings." PLoS ONE. 2015;10(2):e0117424.
Luque AE, Cohn SE, Park J-G, et al. "Depot medroxyprogesterone acetate in combination with a twice-daily lopinavir-ritonavir-based regimen in HIV-infected women showed effective contraception and a lack of clinically significant interactions, with good safety and tolerability: results of the." Antimicrob. Agents Chemother.. 2015;59(4):2094-101.
Firnhaber C, Smeaton LM, Grinsztejn B, et al. "Differences in antiretroviral safety and efficacy by sex in a multinational randomized clinical trial." HIV Clin Trials. 2015;16(3):89-99.
Grant PM, Kitch D, McComsey GA, Tierney C, Ha B, Brown TT. "Differential skeletal impact of tenofovir disoproxil fumarate in young versus old HIV-infected adults." HIV Clin Trials. 2015;16(2):66-71.
Katsounas A, Frank AC, Lempicki RA, Polis MA, Asmuth DM, Kottilil S. "Differential Specificity of Interferon-alpha Inducible Gene Expression in Association with Human Immunodeficiency Virus and Hepatitis C Virus Levels and Declines in vivo." J AIDS Clin Res. 2015;6(1).
Andrade A, Guedj J, Rosenkranz SL, et al. "Early HIV RNA decay during raltegravir-containing regimens exhibits two distinct subphases (1a and 1b)." AIDS. 2015;29(18):2419-26.
Podany AT, Bao Y, Swindells S, et al. "Efavirenz Pharmacokinetics and Pharmacodynamics in HIV-Infected Persons Receiving Rifapentine and Isoniazid for Tuberculosis Prevention." Clin. Infect. Dis.. 2015;61(8):1322-7.
Hennig S, Naiker S, Reddy T, et al. "Effect of SLCO1B1 Polymorphisms on Rifabutin Pharmacokinetics in African HIV-Infected Patients with Tuberculosis." Antimicrob. Agents Chemother.. 2015;60(1):617-20.
Labo N, Miley W, Benson CA, Campbell TB, Whitby D. "Epidemiology of Kaposi's sarcoma-associated herpesvirus in HIV-1-infected US persons in the era of combination antiretroviral therapy." AIDS. 2015;29(10):1217-25.
Dubé MP, Komarow L, Fichtenbaum CJ, et al. "Extended-Release Niacin Versus Fenofibrate in HIV-Infected Participants With Low High-Density Lipoprotein Cholesterol: Effects on Endothelial Function, Lipoproteins, and Inflammation." Clin. Infect. Dis.. 2015;61(5):840-9.
Kendall MA, Tassiopoulos K, McComsey GA, Yin MT. "Fractures Are Not Associated with CD8(+) T Cell Activation: An Analysis of the ACTG ALLRT Study." AIDS Res. Hum. Retroviruses. 2015;31(8):769-71.
Wanga V, Venuto C, Morse GD, et al. "Genomewide association study of tenofovir pharmacokinetics and creatinine clearance in AIDS Clinical Trials Group protocol A5202." Pharmacogenet. Genomics. 2015;25(9):450-61.
Lehmann DS, Ribaudo HJ, Daar ES, et al. "Genome-wide association study of virologic response with efavirenz-containing or abacavir-containing regimens in AIDS clinical trials group protocols." Pharmacogenet. Genomics. 2015;25(2):51-9.
Shiboski CH, Chen H, Secours R, et al. "High Accuracy of Common HIV-Related Oral Disease Diagnoses by Non-Oral Health Specialists in the AIDS Clinical Trial Group." PLoS ONE. 2015;10(7):e0131001.
Tashima KT, Smeaton LM, Fichtenbaum CJ, et al. "HIV Salvage Therapy Does Not Require Nucleoside Reverse Transcriptase Inhibitors: A Randomized, Controlled Trial." Ann. Intern. Med.. 2015;163(12):908-17.
Taiwo BO, Chan ES, Fichtenbaum CJ, et al. "Less Bone Loss With Maraviroc- Versus Tenofovir-Containing Antiretroviral Therapy in the AIDS Clinical Trials Group A5303 Study." Clin. Infect. Dis.. 2015;61(7):1179-88.
Colantuoni E, Rosenblum M. "Leveraging prognostic baseline variables to gain precision in randomized trials." Stat Med. 2015;34(18):2602-17.
Kumarasamy N, Aga E, Ribaudo HJ, et al. "Lopinavir/Ritonavir Monotherapy as Second-line Antiretroviral Treatment in Resource-Limited Settings: Week 104 Analysis of AIDS Clinical Trials Group (ACTG) A5230." Clin. Infect. Dis.. 2015;60(10):1552-8.
Gupta SK, Kitch D, Tierney C, Melbourne K, Ha B, McComsey GA. "Markers of renal disease and function are associated with systemic inflammation in HIV infection." HIV Med.. 2015;16(10):591-8.
Dooley KE, Savic RM, Park J-G, et al. "Novel dosing strategies increase exposures of the potent antituberculosis drug rifapentine but are poorly tolerated in healthy volunteers." Antimicrob. Agents Chemother.. 2015;59(6):3399-405.
Gross R, Zheng L, La Rosa A, et al. "Partner-Focused Adherence Intervention for Second-line Antiretroviral Therapy: A Multinational Randomized Trial (ACTG A5234)." Lancet HIV. 2015;2(1):e12-e19.
Lee AJ, Bosch RJ, Evans SR, et al. "Patterns of peripheral neuropathy in ART-naïve patients initiating modern ART regimen." J. Neurovirol.. 2015;21(2):210-8.
Sha BE, Tierney C, Sun X, et al. "PHARMACOKINETIC EXPOSURE AND VIROLOGIC RESPONSE IN HIV-1 INFECTED PREGNANT WOMEN TREATED WITH LOPINAVIR/RITONAVIR: AIDS CLINICAL TRIALS GROUP PROTOCOL A5153S: A SUBSTUDY TO A5150." Jacobs J AIDS HIV. 2015;1(1).
Decloedt EH, van der Walt JS, McIlleron H, Wiesner L, Maartens G. "The pharmacokinetics of lopinavir/ritonavir when given with isoniazid in South African HIV-infected individuals." Int. J. Tuberc. Lung Dis.. 2015;19(10):1194-6.
Moore CB, Verma A, Pendergrass S, et al. "Phenome-wide Association Study Relating Pretreatment Laboratory Parameters With Human Genetic Variants in AIDS Clinical Trials Group Protocols." Open Forum Infect Dis. 2015;2(1):ofu113.

Pages